-
公开(公告)号：US20230226165A1
公开(公告)日：2023-07-20
申请号：US18178638
申请日：2023-03-06
申请人： Valneva Austria GmbH
CPC分类号： A61K39/12 , A61K39/39 , A61P31/14 , C07K14/18 , C07K14/1825 , C12N7/00 , C12N7/02 , C12N7/06 , A61K2039/5252
摘要： Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
-
2.发明申请公开(公告)号：US20230089695A1
公开(公告)日：2023-03-23
申请号：US17930591
申请日：2021-03-02
申请人： VERSITECH LIMITED
发明人： Honglin Chen , Pui Wang
IPC分类号： A61K39/215 , C07K14/165 , A61K9/00 , C12N7/04 , A61K35/76 , C12N15/86 , C12N7/06
摘要： Live attenuated viruses for protection against the novel coronavirus, designated as Sars-CoV-2 by the World Health Organization (WHO) are provided. The live attenuated chimeric virus strains are based on a live attenuated influenza B virus (LAIVB), used a master backbone, which includes deletion of the viral virulence element, the NS1 (non-structural protein 1) (DeLNS1-B), engineered to express one or more antigens of the Sars-CoV-2 (herein, CoV2Ag). The chimeric virus strain is referred to generally herein, as DelNS1-B-Sars-CoV-2-CoV2Ag. The DelNS1-B-Sars-CoV-2-CoV2Ag strain preferably shows spontaneous cold adaption with preference to grow at 30-33° C. The DelNS1-B-Sars-CoV-2-CoV2Ag strain can be used to protect a subject in need thereof, against a challenge of Sars-CoV-2. DelNS1-B-Sars-CoV-2-CoV2Ag is an important strategy for making highly attenuated and immunogenic live attenuated vaccines with the ability to induce protective immunity against Sars-CoV-2.
-
公开(公告)号：US20220273786A1
公开(公告)日：2022-09-01
申请号：US17548721
申请日：2021-12-13
申请人： Valneva Austria GmbH
摘要： Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
-
公开(公告)号：US11406700B2
公开(公告)日：2022-08-09
申请号：US16840760
申请日：2020-04-06
申请人： Valneva SE
摘要： Described herein are processes for purifying infectious virus particles and uses of protamine in such processes.
-
公开(公告)号：US11331382B2
公开(公告)日：2022-05-17
申请号：US16060054
申请日：2016-12-23
申请人： Valneva Austria GmbH
摘要： Described herein are improved purification methods for Zika virus vaccines and compositions. Also described are Zika vaccines and methods of producing and administering said Zika vaccines to subjects in need thereof.
-
公开(公告)号：US20210187092A1
公开(公告)日：2021-06-24
申请号：US16756227
申请日：2018-10-10
发明人： Rajeev Mhalasakant DHERE , Leena Ravindra YEOLEKAR , Vinit KUMAR , Rohit Bapurav SONAR , Sandeep Dinkar BARASKAR , Rajeev MEHLA , Shashikant Janardan GHODEKAR
摘要： Stable lyophilized immunogenic compositions include inter alia live attenuated recombinant flaviviruses, more preferably live attenuated recombinant dengue viruses, at least one carbohydrate, at least one amino acid and is particularly amenable to rapid freeze-drying treatments wherein, the composition preserves desired characteristics of a virus, including virus viability, immunogenicity and stability. The immunogenic composition is devoid of preservatives, polymers and surfactants. The methods for manufacturing the stable lyophilized immunogenic compositions are also provided.
-
公开(公告)号：US20210095261A1
公开(公告)日：2021-04-01
申请号：US16499355
申请日：2018-03-30
申请人： UNIVERCELLS S.A.
发明人： José CASTILLO , Vasily MEDVEDEV
摘要： The invention provides a method and a kit for combined virus inactivation and capture/purification of a feed containing a protein of interest. The method comprises the steps of: contacting a feed comprising a protein of interest with negatively charged particles or media, conditioning the particles or media such that the pH is acidic thereby inactivating said virus, and eluting said protein of interest.
-
公开(公告)号：US20210093707A1
公开(公告)日：2021-04-01
申请号：US16927086
申请日：2020-07-13
申请人： Valneva Austria GmbH
摘要： Described herein are processes for purifying infectious Zika virus particles and uses of protamine in such processes.
-
公开(公告)号：US20210069359A1
公开(公告)日：2021-03-11
申请号：US16772068
申请日：2018-09-18
摘要： The invention provides a unit operation formed by a device and its use for continuous virus inactivation of a continuous flow of a process fluid. The unit operation formed by a device comprises a single inlet at one end and an outlet at the opposite end and at least one HFI, characterized in that the HFI further comprises at least one installation.
-
公开(公告)号：US10786568B2
公开(公告)日：2020-09-29
申请号：US15906887
申请日：2018-02-27
发明人： Maria P. Limberis , Anna P. Tretiakova , James M. Wilson , Michael Naso , Joost Kolkman , Robert Friesen , Qiang Wang
摘要： A non-replicating recombinant adeno-associated associated virus (rAAV) having an AAV capsid having packaged therein a vector genome which comprises AAV inverted terminal repeat sequences and at least one nucleic acid sequence encoding four different immunoglobulin regions (a), (b), (c) and (d) is provided. The rAAV-expressed immunoglobulins are useful for providing passive immunization against influenza A and influenza B. Also described herein are compositions containing the rAAV. Methods of vaccinating patients against influenza are provided.
-
-
-
-
-
-
-
-
-
搜索结果
440 条记录 (耗时 0.019 秒)
